These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 35331696)

  • 1. Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects.
    Dyck JRB; Sossalla S; Hamdani N; Coronel R; Weber NC; Light PE; Zuurbier CJ
    J Mol Cell Cardiol; 2022 Jun; 167():17-31. PubMed ID: 35331696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardioprotection by SGLT2 Inhibitors-Does It All Come Down to Na
    Trum M; Riechel J; Wagner S
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
    Lan NSR; Fegan PG; Yeap BB; Dwivedi G
    ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions.
    Passantino A; Rizzo C; Scrutinio D; Palazzuoli A
    Heart Fail Rev; 2023 May; 28(3):683-695. PubMed ID: 34725782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients.
    Hwang IC; Cho GY; Yoon YE; Park JJ; Park JB; Lee SP; Kim HK; Kim YJ; Sohn DW
    Cardiovasc Diabetol; 2020 May; 19(1):69. PubMed ID: 32466760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment.
    D'Onofrio N; Sardu C; Trotta MC; Scisciola L; Turriziani F; Ferraraccio F; Panarese I; Petrella L; Fanelli M; Modugno P; Massetti M; Marfella LV; Sasso FC; Rizzo MR; Barbieri M; Furbatto F; Minicucci F; Mauro C; Federici M; Balestrieri ML; Paolisso G; Marfella R
    Mol Metab; 2021 Dec; 54():101337. PubMed ID: 34500107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment.
    Rizzo MR; Di Meo I; Polito R; Auriemma MC; Gambardella A; di Mauro G; Capuano A; Paolisso G
    Pharmacol Res; 2022 Feb; 176():106062. PubMed ID: 35017046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled?
    Pabel S; Hamdani N; Luedde M; Sossalla S
    Curr Heart Fail Rep; 2021 Oct; 18(5):315-328. PubMed ID: 34523061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling.
    Salah HM; Verma S; Santos-Gallego CG; Bhatt AS; Vaduganathan M; Khan MS; Lopes RD; Al'Aref SJ; McGuire DK; Fudim M
    J Cardiovasc Transl Res; 2022 Oct; 15(5):944-956. PubMed ID: 35290593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
    Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
    [No Abstract]   [Full Text] [Related]  

  • 11. SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms.
    Nikolic M; Zivkovic V; Jovic JJ; Sretenovic J; Davidovic G; Simovic S; Djokovic D; Muric N; Bolevich S; Jakovljevic V
    Heart Fail Rev; 2022 May; 27(3):935-949. PubMed ID: 33534040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics.
    Liu Z; Ma X; Ilyas I; Zheng X; Luo S; Little PJ; Kamato D; Sahebkar A; Wu W; Weng J; Xu S
    Theranostics; 2021; 11(9):4502-4515. PubMed ID: 33754074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
    Packer M
    Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na
    Uthman L; Baartscheer A; Bleijlevens B; Schumacher CA; Fiolet JWT; Koeman A; Jancev M; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
    Diabetologia; 2018 Mar; 61(3):722-726. PubMed ID: 29197997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
    Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
    Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis.
    Gronda E; Lopaschuk GD; Arduini A; Santoro A; Benincasa G; Palazzuoli A; Gabrielli D; Napoli C
    Can J Physiol Pharmacol; 2022 Feb; 100(2):93-106. PubMed ID: 35112597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 Inhibitors and Their Antiarrhythmic Properties.
    Kolesnik E; Scherr D; Rohrer U; Benedikt M; Manninger M; Sourij H; von Lewinski D
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects.
    Palmiero G; Cesaro A; Vetrano E; Pafundi PC; Galiero R; Caturano A; Moscarella E; Gragnano F; Salvatore T; Rinaldi L; Calabrò P; Sasso FC
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.